# US 2024/0254558 A1 · Urinary microbiomic profiling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254558 A1
- Document ID: US20240254558A1
- Status: Published application
- Kind: A1
- Application number: 18/603,943
- Filed: 2024-03-13
- Published: 2024-08-01
- Earliest claimed: 2018-07-25
- Assignees: Convergent Genomics, Inc.
- Applicants: Convergent Genomics, Inc.
- Inventors: Trevor Levin; Kevin Phillips; Christian Rees
- Web page: https://patentgrep.com/patent/US20240254558A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6869: Methods for sequencing
- C12Q 1/689: for bacteria
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G16B 40/30: Unsupervised data analysis
- G16B 50/30: Data warehousing; Computing architectures
- G01N 2800/34: Genitourinary disorders
- G01N 2800/348: Urinary tract infections
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Methods and systems for identifying and/or treating urinary disorders are provided. The methods and systems generally operate by obtaining a urine sample from a subject, identifying (such as by using nucleic acid sequencing) an abundance of a first set of one or more microbes (such as one or more bacteria or viruses) in the urine sample, and determining whether the subject suffers from a urinary disorder based on the abundance of the first set of one or more microbes. In some cases, the methods and systems further operate by identifying a second set of microbes to supplement a microbiome in the urinary tract of the subject. In some instances, the methods and systems further operate by treating the urinary disorder using the second set of microbes. In some instances a preservation solution is utilized.

## Claims

### Claim 1

A preservation mixture for preserving nucleic acid molecules and preventing growth of microbes in a urine sample comprising a first chelator, and a second chelator; wherein the first chelator is an iron chelator, and the second chelator is a divalent cation chelator.

### Claim 2 (depends on 1)

The preservation mixture of claim 1, wherein said iron chelator is a siderophore.

### Claim 3 (depends on 1)

The preservation mixture of claim 1, wherein the second chelator is selected from ethylenediamintetraacetic acid (EDTA), nitrilotriacetic acid (NTA), trans-1,2-cyclohexanediaminetetraacetic acid (CyDTA), diethylenetriaminepentaacetic acid (DTPA), glycoletherdiaminetetraacetic acid (GEDTA), triethylenetetramine-N,N,N′,N″,N′″,N″″-hexaacetic acid (TTHA), dihydroxyethylglycine (DHEG), iminodiacetic acid (IDA), nitrilotrimethylphosphonic acid (NTP), N-(2-hydroxyethyl)iminodiacetic acid (HIDA), ethylenediamine-N,N′-dipropionic acid (EDDP), ethylenediaminetetra(methylenephosphonic) acid (EDTPO), nitrilotrimethylphosphonic acid (NTP) or 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA).

### Claim 4 (depends on 1)

The preservation mixture of claim 1, further comprising a nucleic acid compactor.

### Claim 5 (depends on 1)

The preservation mixture of claim 1, further comprising poly-L-lysine.

### Claim 6 (depends on 1)

The preservation mixture of claim 1, further comprising D-alpha-tocopherol polyethylene glycol 1000 succinate.

### Claim 7 (depends on 1)

The preservation mixture of claim 1, further comprising an antimicrobial agent.

### Claim 8 (depends on 7)

The preservation mixture of claim 7, wherein the antimicrobial agent is selected from the group consisting of penicillin, streptomycin, Amphotericin B, and urine Stabilur tablet.

### Claim 9 (depends on 1)

The preservation mixture of claim 1, further comprising penicillin, streptomycin, Amphotericin B, and urine Stabilur tablet.

### Claim 10 (depends on 1)

The preservation mixture of claim 1, further comprising a pH buffer.

### Claim 11 (depends on 1)

The mixture of claim 1, wherein said iron chelator is selected from the group consisting of Enterobactin and Desferrioxamine.

### Claim 12 (depends on 1)

The preservation mixture of claim 1, comprising 100 mM Tris-HCl buffer, 50 mM EDTA, 110 μg poly-L-lysine hydrobromide at a mixed molecular weight of 1,000 Da to 5,000 Da, 1 mg D-alpha-tocopherol polyethylene glycol 1000 succinate (water soluble vitamin E conjugate), 5 μM Enterobactin, 100 units of penicillin, 100 units of streptomycin, and 0.25 μg/mL Amphotericin B.

### Claim 13 (depends on 1)

The preservation mixture of claim 1, wherein:
the first chelator has a stability constant of at least 25.2 for formation of a complex with iron; and
the second chelator is different from said first chelator, wherein said second chelator has a stability constant that is less than 25.2 for formation of a complex with iron.

### Claim 14 (depends on 5)

The preservation mixture of claim 5, wherein the poly-L-lysine is poly-L-lysine hydrobromide.

### Claim 15 (depends on 3)

The preservation mixture of claim 3, wherein the second chelator is Ethylenediaminetetraacetic acid (EDTA).

### Claim 16

A preservation mixture for preserving nucleic acid molecules and preventing growth of microbes in a urine sample comprising an iron chelator and poly-L-lysine.

### Claim 17

A preservation mixture for preserving nucleic acid molecules and preventing growth of microbes in a urine sample comprising a first chelator, wherein the first chelator is an iron chelator, a nucleic acid compactor, and an antimicrobial, wherein the iron chelator is a siderophore and the nucleic acid compactor is poly-L-lysine.

### Claim 18 (depends on 17)

The preservation mixture of claim 17, wherein said iron chelator is selected from the group consisting of enterobactin and Deferoxamine Mesylate.

### Claim 19 (depends on 17)

The preservation mixture of claim 17, further comprising Ethylenediaminetetraacetic acid (EDTA).

### Claim 20 (depends on 17)

The preservation mixture of claim 17, wherein the poly-L-lysine is poly-L-lysine hydrobromide.

### Claim 21 (depends on 17)

The preservation mixture of claim 17, further comprising D-alpha-tocopherol polyethylene glycol 1000 succinate.

### Claim 22 (depends on 17)

The preservation mixture of claim 17, further comprising an antimicrobial selected from the group consisting of penicillin, streptomycin, Amphotericin B, and urine Stabilur tablet.

### Claim 23 (depends on 17)

The preservation mixture of claim 17, further comprising penicillin, streptomycin, Amphotericin B, and urine Stabilur tablet.

### Claim 24 (depends on 17)

The preservation mixture of claim 17, further comprising a pH buffer and a second chelator that is different from said first chelator.

### Claim 25 (depends on 17)

The preservation mixture of claim 17, comprising 100 mM Tris-HCl buffer, 50 mM EDTA, 110 μg poly-L-lysine hydrobromide at a mixed molecular weight of 1,000 Da to 5,000 Da, 1 mg D-alpha-tocopherol polyethylene glycol 1000 succinate (water soluble vitamin E conjugate), 5 μM Enterobactin, 100 units of penicillin, 100 units of streptomycin, and 0.25 μg/mL Amphotericin B.

### Claim 26 (depends on 24)

The preservation mixture of claim 24, wherein:
the iron chelator has a stability constant of at least 25.2 for formation of a complex with iron; and
said second chelator has a stability constant that is less than 25.2 for formation of a complex with iron.
